Topic: non-Hodgkin lymphoma
Fred Hutchinson scientists have identified biomarkers associated with dangerous side effects possible in cancer patients treated with CAR-T cells.
Scientists at Pfizer have figured out how to make blood cancer cells more vulnerable to attack—by driving them from their favorite hiding place.
Kite Pharma has secured a priority review at the FDA for its CAR-T candidate.
Debiopharm has bought a phase 2 antibody-drug conjugate (ADC) from ImmunoGen to add to its clinical-phase cancer pipeline.
The FDA has granted priority review status to Bayer’s copanlisib, setting the PI3K inhibitor up to speed through the regulatory process in 6 months or less.
Kite Pharma was off by 15% in morning trading after it announced the death of a patient in late April of cerebral edema.
French pharma Onxeo is teaming up with CRO Clinigen to bring blood cancer med belinostat to European patients in dire need through a managed access program.
Medivir has posted data from a phase 2 trial of its histone deacetylase inhibitor in patients with cutaneous T-cell lymphoma.
Kite Pharma completed an FDA submission for its CAR-T therapy hours before its self-imposed target passed.
Dutch biotech Synthon joined the race to develop cancer immunotherapies targeting the hot new immune checkpoint CD47.